HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Voyager Therapeutics (NASDAQ:VYGR) and maintained a $30 price target.
May 16, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Voyager Therapeutics and maintained a $30 price target.
The reiteration of a Buy rating and the maintenance of a $30 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100